Successful first human implantation marks a transformational moment in ophthalmology and regenerative medicineBreakthrough marks key clinical ...
Adicet Bio (ACET) announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. “Dosing the first lupus nephritis patient in our Phase 1 ...
Safety 1st’s Nature Next line is made with eco-consciousness in mind — the products use bamboo (a renewable resource), recycled plastic, and bio-plastic (a durable plastic developed from renewable ...
Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical ...
AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced ...
ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of ...
SAN FRANCISCO--(BUSINESS WIRE)--Brightseed, the bioactive discovery company, announced today the launch of Brightseed Bio 01™, a novel dietary hemp fiber to support gut health formulated for use in ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Biohub to unite data, compute, experimental science, and AI to transform and accelerate scientific research REDWOOD CITY, Calif., Nov. 6, 2025 /PRNewswire/ -- Mark Zuckerberg and Priscilla Chan today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback